(Q37232123)

19 August 2017

1 reference

title

Critical molecular abnormalities in high-grade serous carcinoma of the ovary (English)

1 reference

19 August 2017

1 reference

Martin Köbel

1

0 references

C. Blake Gilks

series ordinal

3

object named as

C Blake Gilks

1 reference

19 August 2017

David Huntsman

2

1 reference

19 August 2017

publication date

1 August 2008

1 reference

Expert Reviews in Molecular Medicine

19 August 2017

published in

1 reference

19 August 2017

volume

10

1 reference

19 August 2017

page(s)

e22

1 reference

Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

A mouse model for the molecular characterization of brca1-associated ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Origins and molecular pathology of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of aBRCA1orBRCA2Mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Ovarian cancer: strategies for overcoming resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

A comprehensive modular map of molecular interactions in RB/E2F pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Biologic and Immunologic Therapies for Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

c-MYC: more than just a matter of life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

The p53 pathway: positive and negative feedback loops

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

Ovarian surface epithelium: biology, endocrinology, and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

The fallopian tube: primary site of most pelvic high-grade serous carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells.

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Mechanisms of transcoelomic metastasis in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Distinct subtypes of serous ovarian carcinoma identified by p53 determination

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Grading ovarian serous carcinoma using a two-tier system

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Amplicon profiles in ovarian serous carcinomas

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Inactivation of BRCA1 and BRCA2 in ovarian cancer

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Histopathologic features of genetically determined ovarian cancer

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY.

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

The distal fallopian tube: a new model for pelvic serous carcinogenesis.

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1017%2FS146239940800077X

7 January 2021

10.1017/S146239940800077X

Identifiers

DOI

1 reference

19 August 2017

1 reference